As of 2026-10-12, the EV/EBITDA ratio of Rapid Dose Therapeutics Corp (DOSE.CN) is -14.03. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. DOSE.CN's latest enterprise value is 18.91 mil CAD. DOSE.CN's TTM EBITDA according to its financial statements is -1.35 mil CAD. Dividing these 2 quantities gives us the above DOSE.CN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.1x - 6.1x | 5.1x |
| Forward P/E multiples | 4.1x - 6.1x | 5.1x |
| Fair Price | (0.08) - (0.10) | (0.09) |
| Upside | -177.1% - -197.1% | -187.1% |
| Date | EV/EBITDA |
| 2026-10-09 | -14.03 |
| 2026-10-08 | -14.03 |
| 2026-10-07 | -13.01 |
| 2026-10-06 | -14.55 |
| 2026-10-02 | -14.03 |
| 2026-10-01 | -16.08 |
| 2026-09-30 | -17.10 |
| 2026-09-29 | -15.06 |
| 2026-09-28 | -13.52 |
| 2026-09-25 | -16.08 |
| 2026-09-24 | -15.06 |
| 2026-09-23 | -16.08 |
| 2026-09-22 | -14.55 |
| 2026-09-21 | -14.55 |
| 2026-09-18 | -14.03 |
| 2026-09-17 | -14.55 |
| 2026-09-15 | -14.55 |
| 2026-09-11 | -14.55 |
| 2026-09-10 | -14.55 |
| 2026-09-09 | -15.57 |
| 2026-09-08 | -14.03 |
| 2026-09-04 | -16.08 |
| 2026-09-03 | -15.06 |
| 2026-09-02 | -14.03 |
| 2026-09-01 | -15.06 |
| 2026-08-28 | -16.08 |
| 2026-08-27 | -15.06 |
| 2026-08-26 | -14.03 |
| 2026-08-25 | -15.06 |
| 2026-08-24 | -13.52 |
| 2026-08-20 | -13.01 |
| 2026-08-19 | -14.03 |
| 2026-08-17 | -14.03 |
| 2026-08-14 | -15.57 |
| 2026-08-13 | -15.06 |
| 2026-08-12 | -14.55 |
| 2026-08-11 | -14.03 |
| 2026-08-07 | -13.01 |
| 2026-08-05 | -13.01 |
| 2026-08-04 | -13.01 |
| 2026-07-30 | -13.52 |
| 2026-07-29 | -13.52 |
| 2026-07-27 | -13.52 |
| 2026-07-23 | -13.01 |
| 2026-07-22 | -13.01 |
| 2026-07-21 | -14.55 |
| 2026-07-20 | -14.55 |
| 2026-07-17 | -15.06 |
| 2026-07-16 | -16.59 |
| 2026-07-15 | -16.08 |